請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5256
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳彥榮(Yen-Rong Chen) | |
dc.contributor.author | Hong-Xuan Huang | en |
dc.contributor.author | 黃泓軒 | zh_TW |
dc.date.accessioned | 2021-05-15T17:54:29Z | - |
dc.date.available | 2019-07-29 | |
dc.date.available | 2021-05-15T17:54:29Z | - |
dc.date.copyright | 2014-07-29 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-07-24 | |
dc.identifier.citation | Abel, E.V., Kim, E.J., Wu, J., Hynes, M., Bednar, F., Proctor, E., Wang, L., Dziubinski, M.L., and Simeone, D.M. (2014). The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. PLoS One 9, e91983.
Apostolou, E., and Hochedlinger, K. (2013). Chromatin dynamics during cellular reprogramming. Nature 502, 462-471. Asakuno, K., Kohno, K., Uchiumi, T., Kubo, T., Sato, S., Isono, M., and Kuwano, M. (1994). Involvement of a DNA binding protein, MDR-NF1/YB-1, in human MDR1 gene expression by actinomycin D. Biochem Biophys Res Commun 199, 1428-1435. Asakura, A., and Rudnicki, M.A. (2002). Side population cells from diverse adult tissues are capable of in vitro hematopoietic differentiation. Exp Hematol 30, 1339-1345. Atlasi, Y., Mowla, S.J., Ziaee, S.A., and Bahrami, A.R. (2007). OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 120, 1598-1602. Balko, J.M., Schwarz, L.J., Bhola, N.E., Kurupi, R., Owens, P., Miller, T.W., Gomez, H., Cook, R.S., and Arteaga, C.L. (2013). Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res 73, 6346-6358. Beier, C.P., and Beier, D. (2011). CD133 negative cancer stem cells in glioblastoma. Front Biosci (Elite Ed) 3, 701-710. Bertrand, J., Begaud-Grimaud, G., Bessette, B., Verdier, M., Battu, S., and Jauberteau, M.O. (2009). Cancer stem cells from human glioma cell line are resistant to Fas-induced apoptosis. Int J Oncol 34, 717-727. Bisson, I., and Prowse, D.M. (2009). WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 19, 683-697. Bogaerts, E., Heindryckx, F., Vandewynckel, Y.P., Van Grunsven, L.A., and Van Vlierberghe, H. (2014). The roles of transforming growth factor-beta, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review). Int J Oncol 44, 1015-1022. Cao, L., Shao, M., Schilder, J., Guise, T., Mohammad, K.S., and Matei, D. (2012). Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 31, 2521-2534. Casagrande, F., Cocco, E., Bellone, S., Richter, C.E., Bellone, M., Todeschini, P., Siegel, E., Varughese, J., Arin-Silasi, D., Azodi, M., et al. (2011). Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer 117, 5519-5528. Chen, Y.R., Sekine, K., Nakamura, K., Yanai, H., Tanaka, M., and Miyajima, A. (2009). Y-box binding protein-1 down-regulates expression of carbamoyl phosphate synthetase-I by suppressing CCAAT enhancer-binding protein-alpha function in mice. Gastroenterology 137, 330-340. Chiba, T., Kita, K., Zheng, Y.-W., Yokosuka, O., Saisho, H., Iwama, A., Nakauchi, H., and Taniguchi, H. (2006). Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44, 240-251. Chiou, S.H., Yu, C.C., Huang, C.Y., Lin, S.C., Liu, C.J., Tsai, T.H., Chou, S.H., Chien, C.S., Ku, H.H., and Lo, J.F. (2008). Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 14, 4085-4095. Civenni, G., Malek, A., Albino, D., Garcia-Escudero, R., Napoli, S., Di Marco, S., Pinton, S., Sarti, M., Carbone, G.M., and Catapano, C.V. (2013). RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer. Cancer Res 73, 6816-6827. Cohen, S.B., Ma, W., Valova, V.A., Algie, M., Harfoot, R., Woolley, A.G., Robinson, P.J., and Braithwaite, A.W. (2010). Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing. Oncogene 29, 403-410. Davies, A.H., Reipas, K.M., Pambid, M.R., Berns, R., Stratford, A.L., Fotovati, A., Firmino, N., Astanehe, A., Hu, K., Maxwell, C., et al. (2014). YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer. Stem Cells. Evdokimova, V., Tognon, C., Ng, T., Ruzanov, P., Melnyk, N., Fink, D., Sorokin, A., Ovchinnikov, L.P., Davicioni, E., and Triche, T.J. (2009a). Translational Activation of Snail1 and Other Developmentally Regulated Transcription Factors by YB-1 Promotes an Epithelial-Mesenchymal Transition. Cancer Cell 15, 402-415. Evdokimova, V., Tognon, C., Ng, T., Ruzanov, P., Melnyk, N., Fink, D., Sorokin, A., Ovchinnikov, L.P., Davicioni, E., Triche, T.J., et al. (2009b). Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 15, 402-415. Finkbeiner, M.R., Astanehe, A., To, K., Fotovati, A., Davies, A.H., Zhao, Y., Jiang, H., Stratford, A.L., Shadeo, A., Boccaccio, C., et al. (2009). Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 28, 1421-1431. Fotovati, A., Abu-Ali, S., Wang, P.S., Deleyrolle, L.P., Lee, C., Triscott, J., Chen, J.Y., Franciosi, S., Nakamura, Y., Sugita, Y., et al. (2011). YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Res 71, 5569-5578. Fujii, T., Seki, N., Namoto-Matsubayashi, R., Takahashi, H., Inoue, Y., Toh, U., Kage, M., and Shirouzu, K. (2009). YB-1 prevents apoptosis via the mTOR/STAT3 pathway in HER-2-overexpressing breast cancer cells. Future Oncol 5, 153-156. Galuppo, R., Maynard, E., Shah, M., Daily, M.F., Chen, C., Spear, B.T., and Gedaly, R. (2014). Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/beta-catenin pathways. Anticancer Res 34, 1709-1713. Garibaldi, F., Cicchini, C., Conigliaro, A., Santangelo, L., Cozzolino, A.M., Grassi, G., Marchetti, A., Tripodi, M., and Amicone, L. (2012). An epistatic mini-circuitry between the transcription factors Snail and HNF4alpha controls liver stem cell and hepatocyte features exhorting opposite regulation on stemness-inhibiting microRNAs. Cell Death Differ 19, 937-946. Greaves, M., and Maley, C.C. (2012). Clonal evolution in cancer. Nature 481, 306-313. Gunaratne, P.H. (2009). Embryonic stem cell microRNAs: defining factors in induced pluripotent (iPS) and cancer (CSC) stem cells? Curr Stem Cell Res Ther 4, 168-177. Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. He, B., Barg, R.N., You, L., Xu, Z., Reguart, N., Mikami, I., Batra, S., Rosell, R., and Jablons, D.M. (2005). Wnt signaling in stem cells and non-small-cell lung cancer. Clin Lung Cancer 7, 54-60. Hu, Y., and Smyth, G.K. (2009). ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 347, 70-78. Jurchott, K., Bergmann, S., Stein, U., Walther, W., Janz, M., Manni, I., Piaggio, G., Fietze, E., Dietel, M., and Royer, H.D. (2003). YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 278, 27988-27996. Kang, Y. (2009). Analysis of cancer stem cell metastasis in xenograft animal models. Methods Mol Biol 568, 7-19. Kohno, K., Izumi, H., Uchiumi, T., Ashizuka, M., and Kuwano, M. (2003). The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 25, 691-698. Lasham, A., Print, C.G., Woolley, A.G., Dunn, S.E., and Braithwaite, A.W. (2013). YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem J 449, 11-23. Liao, J., Qian, F., Tchabo, N., Mhawech-Fauceglia, P., Beck, A., Qian, Z., Wang, X., Huss, W.J., Lele, S.B., Morrison, C.D., et al. (2014). Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One 9, e84941. Lu, S.C., and Mato, J.M. (2008). S-Adenosylmethionine in cell growth, apoptosis and liver cancer. Journal of gastroenterology and hepatology 23 Suppl 1, S73-77. Lu, Z.H., Books, J.T., and Ley, T.J. (2005). YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol Cell Biol 25, 4625-4637. Magee, J.A., Piskounova, E., and Morrison, S.J. (2012). Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21, 283-296. Makino, Y., Ohga, T., Toh, S., Koike, K., Okumura, K., Wada, M., Kuwano, M., and Kohno, K. (1996). Structural and functional analysis of the human Y-box binding protein (YB-1) gene promoter. Nucleic Acids Res 24, 1873-1878. Mani, S.A., Guo, W., Liao, M.-J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F., Zhang, C.C., and Shipitsin, M. (2008). The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells. Cell 133, 704-715. Marquardt, J.U., Factor, V.M., and Thorgeirsson, S.S. (2010). Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol 53, 568-577. Ohga, T., Uchiumi, T., Makino, Y., Koike, K., Wada, M., Kuwano, M., and Kohno, K. (1998). Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 273, 5997-6000. Oppitz, U., Schulte, S., Stopper, H., Baier, K., Muller, M., Wulf, J., Schakowski, R., and Flentje, M. (2002). In vitro radiosensitivity measured in lymphocytes and fibroblasts by colony formation and comet assay: comparison with clinical acute reactions to radiotherapy in breast cancer patients. Int J Radiat Biol 78, 611-616. Park, S.W., Do, H.J., Ha, W.T., Han, M.H., Song, H., Uhm, S.J., Chung, H.J., and Kim, J.H. (2014). Differential expression of ETS family transcription factors in NCCIT human embryonic carcinoma cells upon retinoic acid-induced differentiation. Biol Pharm Bull 37, 659-665. Piccirillo, S.G., Reynolds, B.A., Zanetti, N., Lamorte, G., Binda, E., Broggi, G., Brem, H., Olivi, A., Dimeco, F., and Vescovi, A.L. (2006). Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444, 761-765. Sarvi, S., Mackinnon, A.C., Avlonitis, N., Bradley, M., Rintoul, R.C., Rassl, D.M., Wang, W., Forbes, S.J., Gregory, C.D., and Sethi, T. (2014). CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res 74, 1554-1565. Sell, S. (2004). Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 51, 1-28. Serio, R.N. (2014). Wnt of the Two Horizons: Putting Stem Cell Self-Renewal and Cell Fate Determination into Context. Stem Cells Dev. Shenoy, A.K., Fisher, R.C., Butterworth, E.A., Pi, L., Chang, L.J., Appelman, H.D., Chang, M., Scott, E.W., and Huang, E.H. (2012). Transition from colitis to cancer: high Wnt activity sustains the tumor-initiating potential of colon cancer stem cell precursors. Cancer Res 72, 5091-5100. Singh, A., and Settleman, J. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751. Singh, S.K., Clarke, I.D., Terasaki, M., Bonn, V.E., Hawkins, C., Squire, J., and Dirks, P.B. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res 63, 5821-5828. Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue, H., Pastorino, S., Yang, M., Hoffman, R.M., Kesari, S., et al. (2011). Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A 108, 4274-4280. Stadtfeld, M., and Hochedlinger, K. (2010). Induced pluripotency: history, mechanisms, and applications. Genes Dev 24, 2239-2263. Stein, U., Jurchott, K., Walther, W., Bergmann, S., Schlag, P.M., and Royer, H.D. (2001). Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J Biol Chem 276, 28562-28569. Strazzabosco, M., and Fabris, L. (2013). The balance between Notch/Wnt signaling regulates progenitor cells' commitment during liver repair: mystery solved? J Hepatol 58, 181-183. To, K., Fotovati, A., Reipas, K.M., Law, J.H., Hu, K., Wang, J., Astanehe, A., Davies, A.H., Lee, L., Stratford, A.L., et al. (2010). Y-Box Binding Protein-1 Induces the Expression of CD44 and CD49f Leading to Enhanced Self-Renewal, Mammosphere Growth, and Drug Resistance. Cancer Research 70, 2840-2851. Trosko, J.E. (2014). Induction of iPS cells and of cancer stem cells: the stem cell or reprogramming hypothesis of cancer? Anatomical record 297, 161-173. Vangipuram, S.D., Buck, S.A., and Lyman, W.D. (2012). Wnt pathway activity confers chemoresistance to cancer stem-like cells in a neuroblastoma cell line. Tumour Biol 33, 2173-2183. Visvader, J.E. (2011). Cells of origin in cancer. Nature 469, 314-322. Wolffe, A.P. (1994). Structural and functional properties of the evolutionarily ancient Y-box family of nucleic acid binding proteins. Bioessays 16, 245-251. Yamashita, T., Ji, J., Budhu, A., Forgues, M., Yang, W., Wang, H.Y., Jia, H., Ye, Q., Qin, L.X., Wauthier, E., et al. (2009). EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136, 1012-1024. Yang, C.M., and Shinkai, Y. (2013). Prdm12 is induced by retinoic acid and exhibits anti-proliferative properties through the cell cycle modulation of P19 embryonic carcinoma cells. Cell Struct Funct 38, 197-206. Yang, K., Chen, X.Z., Zhang, B., Yang, C., Chen, H.N., Chen, Z.X., Zhou, Z.G., Chen, J.P., and Hu, J.K. (2011). Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis. Int J Biol Markers 26, 173-180. Yang, W., Yan, H.X., Chen, L., Liu, Q., He, Y.Q., Yu, L.X., Zhang, S.H., Huang, D.D., Tang, L., Kong, X.N., et al. (2008a). Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 68, 4287-4295. Yang, Z.F., Ho, D.W., Ng, M.N., Lau, C.K., Yu, W.C., Ngai, P., Chu, P.W.K., Lam, C.T., Poon, R.T.P., and Fan, S.T. (2008b). Significance of CD90(+) cancer stem cells in human liver cancer. Cancer Cell 13, 153-166. Yasen, M., Kajino, K., Kano, S., Tobita, H., Yamamoto, J., Uchiumi, T., Kon, S., Maeda, M., Obulhasim, G., Arii, S., et al. (2005). The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res 11, 7354-7361. Zeilstra, J., Joosten, S.P., Dokter, M., Verwiel, E., Spaargaren, M., and Pals, S.T. (2008). Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 68, 3655-3661. Zhao, Y., Bao, Q., Schwarz, B., Zhao, L., Mysliwietz, J., Ellwart, J., Renner, A., Hirner, H., Niess, H., Camaj, P., et al. (2014). Stem cell-like side populations in esophageal cancer: a source of chemotherapy resistance and metastases. Stem Cells Dev 23, 180-192. Zhou, S., Schuetz, J.D., Bunting, K.D., Colapietro, A.M., Sampath, J., Morris, J.J., Lagutina, I., Grosveld, G.C., Osawa, M., Nakauchi, H., et al. (2001). The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7, 1028-1034. Zhou, W., Lv, R., Qi, W., Wu, D., Xu, Y., Liu, W., Mou, Y., and Wang, L. (2014). Snail contributes to the maintenance of stem cell-like phenotype cells in human pancreatic cancer. PLoS One 9, e87409. Zhu, D., Wan, X., Huang, H., Chen, X., Liang, W., Zhao, F., Lin, T., Han, J., and Xie, W. (2014). Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell-like side population cells. Oncol Rep 31, 727-736. Zubeldia, I.G., Bleau, A.M., Redrado, M., Serrano, D., Agliano, A., Gil-Puig, C., Vidal-Vanaclocha, F., Lecanda, J., and Calvo, A. (2013). Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFbeta1-targeting peptides P17 and P144. Exp Cell Res 319, 12-22. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5256 | - |
dc.description.abstract | 肝癌是世界上致死率前三名的癌症,而其高復發率、高轉移率及抗藥性是現今治療上的主要難題。而近年來快速發展的癌幹細胞理論,提供了一個新的癌症治療觀點。癌幹細胞是腫瘤中存在的類幹細胞群落,具有生長、分化及自我更新的能力。這些癌幹細胞能夠獨立生長分化為腫瘤細胞進而形成腫瘤,為癌症的起始細胞。同時其對傳統癌症藥物具有較高的耐受性,能在化療過程中維持其細胞群落,而在化療結束後繼續分化生長,造成腫瘤復發;除此之外,近年來的研究亦顯示這些癌幹細胞的種種特性如高遷移性、免疫特異性和代謝特殊性,都遠不同於我們原本對癌細胞的認識,成為癌症治療上的缺口,因此發展針對癌幹細胞的治療方法將是未來癌症治療的方向。而多功能蛋白質 YB-1 已被發現在許多癌症中,具有促進幹細胞標記表現、提高癌細胞的移動性和提升抗藥基因表現等癌幹細胞常見的特性;此外在肝臟的發育及再生的過程中, YB-1 亦被發現是重要的調控者,顯示其在幹細胞性質調控上的重要性。
為了進一步研究 YB-1 是否為肝癌幹細胞中的重要調控者,我利用 Sphere Forming 的方式培養肝癌幹細胞,發現在 Sphere 形成過程中, YB-1 和其他多能基因的表現是提升的;進一步利用 RNA 干擾的方式降低 YB-1 表現後,亦發現形成 Sphere 及細胞自我更新的能力明顯下降,而 YB-1 抑制細胞株中癌幹細胞的比例也有所下降;而在肝癌細胞在形成 Sphere 後 YB-1 的核轉移,暗示了其在肝癌幹細胞種基因調控的功能。此外在抑制 YB-1表現後肝癌細胞株的幹細胞標記、細胞移動力還有抗藥基因的表現皆下降;而細胞凋亡的基因反而上升。這些結果可能由 YB-1 影響 Wnt/β-catenin 路徑和表觀遺傳調控因子有關。從以上結果可知 YB-1 在肝癌幹細胞中具有關鍵的角色。 | zh_TW |
dc.description.abstract | Hepatocellular Carcinoma (HCC) is the third cause of cancer mortality in the world. The important issues for the treatment of HCC are the high recurrence rate, easy metastasis and drug resistance. Recently, the concept of cancer stem cells (CSCs) provides a new consideration in the cancer therapy including HCC. Cancer stem cells are a subpopulation of cells in the tumor, which have the capability of self-renewal and differentiation and drug resistance in chemotherapy. Previous studies showed that many properties of CSCs, such as high cell mobility, evading immune destruction and reprogramming of energy metabolism, are very different from the original understanding of cancer. As a result, development of the therapy targeting CSCs is one of the novel therapeutic strategies for the cancer in the future. YB-1 is a protein with multiple functions, which has been found associated with many kinds of cancers. YB-1 can increase the expression of stemness marker genes, enhance cell mobility and up-regulate MDR gene expression. Besides, YB-1 is known as a significant regulator during liver development and regeneration.
To investigate the regulatory function of YB-1 in CSCs of HCC, I used sphere forming method to enrich CSCs. In the sphere cells, the expression of YB-1 and some pluripotent genes was up-regulated. In addition, the sphere forming ability of YB-1-shRNA knockdown HuH7 HCC cell line was decreased. YB-1 would translocalize to the nucleus of sphere forming cells or side-population cells, and the cancer stem cell population sorted from HCC cell line. These results indicated YB-1 might be involved in the transcriptional regulation in the cancer stem cell-like cells in HCC. Additionally, knock down of YB-1 also down-regulated the stemness, drug resistance and epithelial-mesenchymal transition (EMT) genes expression by qPCR analysis. The detail mechanism would be regulated by Wnt/β-catenin pathway and epigenetic regulation. From these results, YB-1 may play a key role in HCC cancer stem cells. | en |
dc.description.provenance | Made available in DSpace on 2021-05-15T17:54:29Z (GMT). No. of bitstreams: 1 ntu-103-R01b22022-1.pdf: 1840660 bytes, checksum: 7174e20b49ebaa16de6c65b846bf221b (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | Verification letter from the Oral Examination Committee i
致謝 ii Abstract iii 中文摘要 v Table of Contents vi List of Figures ix List of Tables x Chapter 1. Introduction 1 1.1 Cancer and Cancer Stem Cell 1 1.1.1 Cancer Initiation 1 1.1.2 Characteristics of cancer stem cells 2 1.2 Origin of cancer stem cells 2 1.2.1 Isolation of cancer stem cells 3 1.3 Molecular Regulation of CSC 4 1.3.1 Self-renewal 4 1.3.2 Differentiation 5 1.3.3 Metastasis 6 1.4 Wnt/β-catenin Signaling 6 1.4.1 Cancer Therapies of Targeting Cancer stem cells 8 1.5 YB-1 8 1.5.1 YB-1, Cancer and Stem Cell Regulation 9 1.5.2 YB-1, liver development and regeneration 10 1.5.3 YB-1, Liver disease, and Malignancy 10 1.6 Motivation and aim 11 1.7 Flow Chart 12 Chapter 2. Materials and Methods 13 2.1 Cell lines 13 2.2 Sphere formation assay 13 2.3 RNA Extraction 13 2.4 cDNA preparation and Quantitative PCR 14 2.5 Cellular protein extraction 14 2.6 Western blot 15 2.7 Stable knock down clone establishment 16 2.8 Immunofluorescent staining and image processing 16 2.9 Colony formation assay 17 2.10 Anti-cancer drug treated and MTT assay 17 2.11 Flow Cytometry 18 2.12 Statistics 18 Chapter 3. Results 19 3.1 HCC cell lines could form spheroid cells 19 3.2 YB-1 was up-regulated during sphere forming 19 3.3 YB-1 translocated into nucleus in sphere cells 19 3.4 The self-renewal ability of YB-1 KD cells decreased 20 3.5 The stem cell population would be regulated by YB-1 20 3.6 The pluripotent genes were downregulated in YB-1 KD cells 21 3.7 The pluripotent genes were up-regulated in sphere cells 21 3.8 EMT related genes were altered in different YB-1 expression pattern 22 3.9 KD YB-1 cells had low ability of drug resistance 22 3.10 Increase the proapoptotic genes in YB-1 KD cells 22 3.11 Wnt/β-catenin pathway might be regulated by YB-1 23 3.12 Epigenetic modulators were affected after Knock down of YB-1 24 Chapter 4. Discussion and Conclusion 25 Figures and Tables 28 Appendix 55 List of Abbreviations 55 Supplementary Data 56 Reference 57 | |
dc.language.iso | en | |
dc.title | Y-box binding protein 1 於肝癌幹細胞之功能解析 | zh_TW |
dc.title | Characterization of Y-box binding protein 1 in Hepatocellular Carcinoma Stem Cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳俊任(Chun-Jen Chen),冀宏源(Hung-Yuan Chi),吳金洌(Jen-Leih Wu),鄭永銘(??Yung-Ming Jeng) | |
dc.subject.keyword | 肝癌,癌幹細胞,YB-1, | zh_TW |
dc.subject.keyword | Hepatocellular Carcinoma,Cancer Stem Cell,YB-1, | en |
dc.relation.page | 65 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2014-07-25 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf | 1.8 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。